Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
公司代碼DNA
公司名稱Ginkgo Bioworks Holdings Inc
上市日期Apr 19, 2021
CEOKelly (Jason)
員工數量834
證券類型Ordinary Share
年結日Apr 19
公司地址27 Drydock Avenue
城市BOSTON
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編02210
電話18774425362
網址https://investors.ginkgobioworks.com/
公司代碼DNA
上市日期Apr 19, 2021
CEOKelly (Jason)